- Home
- JFU vs PRTG Comparison
JFU vs PRTG Comparison
Compare JFU & PRTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JFU
- PRTG
- Stock Information
- Founded
- JFU 2006
- PRTG 1973
- Country
- JFU China
- PRTG British Virgin Islands
- Employees
- JFU N/A
- PRTG N/A
- Industry
- JFU Finance: Consumer Services
- PRTG Oil & Gas Production
- Sector
- JFU Finance
- PRTG Energy
- Exchange
- JFU Nasdaq
- PRTG Nasdaq
- Market Cap
- JFU 17.1M
- PRTG 17.7M
- IPO Year
- JFU 2019
- PRTG N/A
- Fundamental
- Price
- JFU $1.40
- PRTG $5.69
- Analyst Decision
- JFU
- PRTG
- Analyst Count
- JFU 0
- PRTG 0
- Target Price
- JFU N/A
- PRTG N/A
- AVG Volume (30 Days)
- JFU 2.9K
- PRTG 234.2K
- Earning Date
- JFU 01-01-0001
- PRTG 08-26-2025
- Dividend Yield
- JFU N/A
- PRTG N/A
- EPS Growth
- JFU N/A
- PRTG N/A
- EPS
- JFU 0.09
- PRTG N/A
- Revenue
- JFU $40,614,155.00
- PRTG N/A
- Revenue This Year
- JFU N/A
- PRTG N/A
- Revenue Next Year
- JFU N/A
- PRTG N/A
- P/E Ratio
- JFU $15.08
- PRTG N/A
- Revenue Growth
- JFU N/A
- PRTG N/A
- 52 Week Low
- JFU $1.01
- PRTG $2.10
- 52 Week High
- JFU $3.60
- PRTG $23.01
- Technical
- Relative Strength Index (RSI)
- JFU 50.23
- PRTG 39.99
- Support Level
- JFU $1.36
- PRTG $5.24
- Resistance Level
- JFU $1.48
- PRTG $6.84
- Average True Range (ATR)
- JFU 0.07
- PRTG 0.76
- MACD
- JFU -0.01
- PRTG -0.09
- Stochastic Oscillator
- JFU 21.13
- PRTG 18.10
About JFU 9F Inc.
9F Inc is a financial account platform integrating and personalizing financial services in China. It provides a range of financial products and services across online lending, wealth management, and payment facilitation, all integrated under a single digital financial account. The company generates the majority of its revenue from Loan facilitation services. All its revenues are generated from the People's Republic of China.
About PRTG Portage Biotech Inc.
Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.